Medical research

Ide-cel beneficial in relapsed, refractory multiple myeloma

For patients with pretreated relapsed and refractory multiple myeloma, idecabtagene vicleucel (ide-cel), a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy, prolongs progression-free survival and ...

page 8 from 40